On Thursday, Shares of Horizon Pharma PLC (NASDAQ:HZNP), gained 1.04% to $17.49.
Horizon Pharma, declared the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/753,195 (U.S. publication number 2015-0297543), entitled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” that covers the U.S. approved medicine VIMOVO® (naproxen/esomeprazole) delayed release tablets.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), declined -0.41% to $67.31, during its last trading session.
Bristol-Myers Squibb Company, declared that the U.S. Food and Drug Administration (FDA) has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection counting total lymphadenectomy. This approval is based on clinical data from a pivotal Phase 3 trial, CA184-029 (EORTC 18071), which demonstrated Yervoy 10 mg/kg significantly improved recurrence-free survival (RFS) vs. placebo in this setting, with a 25 percent reduction in the risk of recurrence or death. The median RFS was 26 months (95% CI: 19, 39) for Yervoy vs. 17 months (95% CI: 13, 22) for placebo (hazard ratio [HR]=0.75; 95% CI: 0.64, 0.90; p<0.002). Yervoy is the first and only FDA-approved immune checkpoint inhibitor in the adjuvant treatment for fully resected Stage III melanoma (lymph node >1 mm).
Resectable, Stage III melanoma represents 5 percent, or about 3,100 cases, of all new melanoma cases diagnosed annually. This stage of melanoma can be aggressive, with a 60 percent risk of recurrence after surgery. Despite the risk of disease recurrence among Stage III melanoma patients following resection, there are limited treatment options available to assist reduce the risk of recurrence after surgery.
Yervoy is associated with a Boxed Warning and can result in severe to fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (counting toxic epidermal necrolysis), neuropathy, and endocrinopathy. Please see below for additional Important Safety Information, counting Boxed WARNING regarding immune-mediated adverse reactions.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession.
Finally, Shares of McDermott International (NYSE:MDR), ended its last trade with -3.52% loss, and closed at $4.66.
McDermott International, declared it has received regulatory approval for its McDermott Marine Construction Ghana Limited (MMCGL) joint venture to pursue key offshore opportunities in Ghana. McDermott and MMCGL officials made the declaration during the 2015 Africa Oil Week in Cape Town, South Africa.
The Petroleum Commission Ghana notified MMCGL that it has been granted regulatory approval to develop contracting abilities to support the country’s burgeoning subsea and offshore engineering, procurement, construction and installation (EPCI) industry.
McDermott International, Inc. is an engineering, procurement, construction and installation (EPCI) company focused on designing and executing offshore oil and gas projects across the world. The Company’s operating segments comprise Asia Pacific, Americas, Middle East and North Sea and Africa. The Asia Pacific segment serves customers in Australia, Indonesia, Vietnam, Malaysia, Thailand and India.